These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 10687980

  • 1. Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors.
    Morris MJ, Bosl GJ.
    J Urol; 2000 Mar; 163(3):796-801. PubMed ID: 10687980
    [Abstract] [Full Text] [Related]

  • 2. Re: Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors.
    Schatte EC, Lerner SP.
    J Urol; 2000 Nov; 164(5):1670. PubMed ID: 11203071
    [No Abstract] [Full Text] [Related]

  • 3. [The role of tumor markers in the treatment of germ cell tumor].
    Niwakawa M, Tobisu K.
    Gan To Kagaku Ryoho; 2001 Aug; 28(8):1159-65. PubMed ID: 11525037
    [Abstract] [Full Text] [Related]

  • 4. The management of patients with clinical stage I nonseminomatous testicular tumors and persistently elevated serologic markers.
    Saxman SB, Nichols CR, Foster RS, Messemer JE, Donohue JP, Einhorn LH.
    J Urol; 1996 Feb; 155(2):587-9. PubMed ID: 8558665
    [Abstract] [Full Text] [Related]

  • 5. [Usefulness of tumor markers in the treatment of germ cell tumors].
    Germá Lluch JR, García del Muro X, Galán MC.
    Arch Esp Urol; 2000 Feb; 53(6):460-8. PubMed ID: 11002513
    [Abstract] [Full Text] [Related]

  • 6. Tumor marker levels in post-chemotherapy cystic masses: clinical implications for patients with germ cell tumors.
    Beck SD, Patel MI, Sheinfeld J.
    J Urol; 2004 Jan; 171(1):168-71. PubMed ID: 14665869
    [Abstract] [Full Text] [Related]

  • 7. [Testis cancer markers. Clinical use].
    Salesi N, Di Cocco B, Alghisi F, Calabretta F, Bossone G.
    Minerva Med; 2002 Oct; 93(5):365-9. PubMed ID: 12410169
    [Abstract] [Full Text] [Related]

  • 8. Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers.
    Habuchi T, Kamoto T, Hara I, Kawai K, Nakao M, Nonomura N, Kobayashi T, Ogawa O, Kamidono S, Akaza H, Okuyama A, Kato T, Miki T.
    Cancer; 2003 Oct 15; 98(8):1635-42. PubMed ID: 14534879
    [Abstract] [Full Text] [Related]

  • 9. Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor.
    You B, Fronton L, Boyle H, Droz JP, Girard P, Tranchand B, Ribba B, Tod M, Chabaud S, Coquelin H, Fléchon A.
    Urology; 2010 Aug 15; 76(2):423-9.e2. PubMed ID: 20472276
    [Abstract] [Full Text] [Related]

  • 10. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors.
    Fizazi K, Culine S, Kramar A, Amato RJ, Bouzy J, Chen I, Droz JP, Logothetis CJ.
    J Clin Oncol; 2004 Oct 01; 22(19):3868-76. PubMed ID: 15302906
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Tumor markers in patients with non-seminomatous germ cell tumors of the testis.
    Willemse PH, Sleijfer DT, Schraffordt Koops H, De Bruijn HW, Oosterhuis JW, Brouwers TM, Ockhuizen T, Marrink J.
    Oncodev Biol Med; 1981 Oct 01; 2(1-2):117-28. PubMed ID: 6170952
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Diagnostic value of alpha 1-fetoprotein and beta-human chorionic gonadotropin in infancy and childhood.
    Schneider DT, Calaminus G, Göbel U.
    Pediatr Hematol Oncol; 2001 Oct 01; 18(1):11-26. PubMed ID: 11205836
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Early identification of therapeutic failure in nonseminomatous germ cell tumors by assessing serum tumor marker decline during chemotherapy: still not ready for routine clinical use.
    Toner GC.
    J Clin Oncol; 2004 Oct 01; 22(19):3842-5. PubMed ID: 15302908
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. 125I-labelled human chorionic gonadotrophin (hCG) as an elimination marker in the evaluation of hCG decline during chemotherapy in patients with testicular cancer.
    Christensen TB, Engbaek F, Marqversen J, Nielsen SI, Kamby C, von der Maase H.
    Br J Cancer; 1999 Jul 01; 80(10):1577-81. PubMed ID: 10408402
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.